title: Positive inotropic effects mediated by alpha 1 adrenoceptors in intact human subjects.
abstract: The role of alpha 1-adrenergic receptors (adrenoceptors) on cardiac contractility was investigated in human subjects. The effect of methoxamine, a selective alpha-adrenoceptor agonist, and angiotensin II, on cardiac contractility was determined by means of noninvasive assessment of the slope of the end-systolic pressure (ESP)/end-systolic dimension (ESD) relationship. The slope (m) of this ratio was significantly higher with methoxamine (17.0; SD = 9.0 mm Hg/mm) than with angiotensin II (4.8; SD = 1.9 mm Hg/mm) (p less than 0.05). Slopes with methoxamine were higher when heart rates (HRs) were reflexly reduced, and were significantly diminished when reflex bradycardia was prevented by atropine (p less than 0.05) or atrial pacing (p less than 0.01). Previous treatment with propranolol did not modify m values with methoxamine (m = 15.5; SD = 4.4 mm Hg/mm). Phentolamine, given at peak methoxamine effect, did not consistently modify m values, resulting in an average slope not significantly different from that obtained with methoxamine alone. However, the addition of phentolamine did not cause an increase in ESDs at each level of ESP with respect to methoxamine. In the same subjects, infusion of phentolamine after angiotensin did not modify ESDs at comparable ESP levels. These findings suggest the existence of a positive inotropic effect mediated by alpha 1 adrenoceptors in the intact human heart.
authors: Unidad de Exploración Cardiovascular, Servicio de Medicina Interna, Maternidad Concepción Palacios, Caracas, Venezuela.
authors: R
authors: R
authors: Curiel
authors: J
authors: J
authors: Pérez-González
authors: N
authors: N
authors: Brito
authors: R
authors: R
authors: Zerpa
authors: D
authors: D
authors: Téllez
authors: J
authors: J
authors: Cabrera
authors: C
authors: C
authors: Curiel
authors: L
authors: L
authors: Cubeddu
mesh_terms: D000328:Adult; D000804:Angiotensin II / Q000494:pharmacology; D001285:Atropine / Q000008:administration & dosage / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002304:Cardiac Pacing, Artificial; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008729:Methoxamine / Q000008:administration & dosage / Q000494:pharmacology; D009200:Myocardial Contraction / Q000187:drug effects*; D010646:Phentolamine / Q000008:administration & dosage / Q000494:pharmacology; D011433:Propranolol / Q000008:administration & dosage / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000502:physiology*; D013268:Stimulation, Chemical
chemical_list: D011942:Receptors, Adrenergic, alpha; D000804:Angiotensin II; D001285:Atropine; D011433:Propranolol; D008729:Methoxamine; D010646:Phentolamine